ClinicalTrials.gg
CompletedNCT07534176Updated Sep 18, 2026

To Evaluate the Impact of Smoking on PK After Single-dose Oral Administration of GS1-144 Tablets .

A Phase 1 interventional study of GS1-144 tablets in Postmenopause, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to female participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
40 Years to 65 Years
Sex
Female
01

Study summary

A Drug-Drug Interaction Study to Evaluate the Effect of Smoking (CYP1A2 Inducer) on the Pharmacokinetics Following a Single Oral Dose of GS1-144 Tablets in Chinese Healthy Postmenopausal Female Trial Participants

Read the detailed description

This drug-drug interaction study adopts an open-label, parallel design to evaluate the effect of smoking on the PK following a single oral dose of GS1-144 tablets in Chinese healthy postmenopausal female trial participants.

02

Conditions studied

  • Postmenopause
03

In context

Lead sponsor

Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 112 studies on the registry; 48 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1)40 to 65 years of age (inclusive) at the time of signing the form (ICF).

2)Trial participants are healthy females who meet any of the following criteria during screening:

  1. Consecutive spontaneous amenorrhea ≥ 12 months.
  2. Consecutive spontaneous amenorrhea ≥ 6 months but \< 12 months, with serum follicle-stimulating hormone (FSH) levels > 40 IU/L.
  3. ≥ 6 weeks after bilateral oophorectomy.
  4. History of hysterectomy with preservation of one or both ovaries and FSH levels > 40 IU/L.

    3)Body weight ≥ 45 kg, and (BMI) within the range of 18-28 kg/m2 (inclusive).

    4)Able to communicate well with the investigator, understand and comply with all study requirements, voluntarily agree to participate in the trial, and understand and voluntarily sign the ICF.

    5)Smoker:smoking ≥ 10 cigarettes per day within 6 months prior to screening, and urinary cotinine level ≥ 1,000 ng/mL at screening. Smokers will be required to continue smoking in designated areas according to their habits during the study.

    6)Non-smoker: no smoking within 6 months prior to screening, and urinary cotinine level \< 200 ng/mL at screening.

Exclusion criteria

Exclusion Criteria:

  1. Known history of to the drug, any of its , or related formulations; or a history of allergic disorders (including but not limited to asthma, urticaria); or being allergy-prone (e.g., known allergy to two or more substances).
  2. History or current diagnosis of diseases of the circulatory, digestive, urinary, respiratory, endocrine and metabolic, hematological and lymphatic, immune, psychiatric and neurological, or dermatological systems, and deemed unsuitable for participation by the investigator.
  3. History of severe infection, serious trauma, or major surgery within 6 months prior to screening, or planning to undergo surgery during the trial.
  4. Blood donation or blood loss ≥ 400 mL, or receipt of blood transfusion within 3 months prior to screening, or planning to donate blood within 1 month after the end of the trial.
  5. Use of any prescription medications [including but not limited to drugs known to alter hepatic enzyme activity (e.g., , sex hormones, anticonvulsants, cyclosporine)] within 4 weeks prior to screening, or use of any over-the-counter (OTC) medications (including but not limited to herbal medicines, herbal compound prescriptions, health supplements) or vitamin supplements within 2 weeks prior to screening.
  6. Trial participants with abnormal findings in physical examination, chest X-ray, abdominal and urinary ultrasound, genital ultrasound, thyroid and parathyroid ultrasound, or laboratory tests at screening, which are deemed unsuitable for participation by the investigator.
  7. During screening or on D-1, any of the following liver function test results as follows: (ALT) and/or aspartate aminotransferase (AST) ≥ 1.5 × (ULN), or total (TBIL) ≥ 1.2 × ULN.
  8. Abnormal vital signs and deemed unsuitable for participation by the investigator, or systolic blood pressure ≥ 150 mmHg and/or diastolic blood pressure ≥ 100 mmHg during screening.
  9. Abnormal 12-lead findings and deemed unsuitable for participation by the investigator, or > 470 ms (Fridericia's formula: QTcF = QT/RR0.33, RR = 60/heart rate) during screening.
  10. Positive test results for (HIV) antibody, surface antigen (HBsAg), virus (HCV) antibody, or Treponema pallidum antibody (TP-Ab) during screening.
  11. Participation in another clinical trial within 3 months prior to screening (except for trial participants who did not receive any investigational intervention), or current participation in any other clinical trial.
  12. Current or past history of drug abuse within 1 year, or positive urine multi-drug test panel.
  13. Positive alcohol breath test or history of excessive alcohol consumption (defined as >14 units of alcohol per week) within 3 months prior to screening (One standard alcohol unit is equivalent to 17.5 mL or 14 g of pure ethanol. Alcohol content is labeled by volume (ABV) for all beverage types. This corresponds approximately to 35 mL of 50% spirits or 350 mL of 5% beer), or unwillingness to abstain from alcohol or any alcohol-containing products during the trial.
  14. Consumption of food or beverages that may affect drug metabolism (e.g., containing grapefruit, starfruit, or their products) within 48 hours prior to admission.
  15. Excessive consumption of tea, coffee, or caffeinated beverages (>8 cups per day, 1 cup=250 mL) within 3 months prior to screening; or consumption of any food or beverage containing or metabolized to caffeine or xanthine (e.g., coffee, tea, chocolate, cola) within 24 hours prior to admission.
  16. Pregnant or lactating women, or those who have a positive pregnancy test result.
  17. Poor venous access, a history of difficult venipuncture, intolerance to venipuncture/intravenous indwelling needle, or needle/blood phobia.
  18. Other conditions deemed unsuitable by the investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    GS1-144 tablets

    Drug: GS1-144 tablets

Interventions

  • All trial participants will receive the investigational drug (GS1-144 tablets) at a dose of 30 mg.

06

What researchers measure

Primary outcomes

  1. Primary PK parameters for GS1-144: Cmax.

    Time frame: up to 72 hours

  2. Primary PK parameters for GS1-144: AUC0-t.

    Time frame: up to 72 hours

  3. Primary PK parameters for GS1-144: AUC0-∞.

    Time frame: up to 72 hours

  4. Secondary PK parameters of GS1-144: Tmax.

    Time frame: up to 72 hours

  5. Secondary PK parameters of GS1-144: elimination rate constant (λz).

    Time frame: up to 72 hours

  6. Secondary PK parameters of GS1-144: t1/2.

    Time frame: up to 72 hoursv

  7. Secondary PK parameters of GS1-144:CL/F.

    Time frame: up to 72 hours

  8. Secondary PK parameters of GS1-144: Vd/F.

    Time frame: up to 72 hours

  9. Secondary PK parameters of GS1-144: AUC_%Extrap.

    Time frame: up to 72 hours

Secondary outcomes

  1. PK parameters of the primary metabolite M1: Cmax.

    Time frame: up to 72 hours

  2. PK parameters of the primary metabolite M1: AUC0-t.

    Time frame: up to 72 hours

  3. PK parameters of the primary metabolite M1: AUC0-∞.

    Time frame: up to 72 hours

  4. :PK parameters of the primary metabolite M1: Tmax.

    Time frame: up to 72 hours

  5. PK parameters of the primary metabolite M1: λz.

    Time frame: up to 72 hours

  6. PK parameters of the primary metabolite M1: t1/2.

    Time frame: up to 72 hours

  7. PK parameters of the primary metabolite M1: AUC_%Extrap.

    Time frame: up to 72 hours

  8. Adverse events (AEs).

    Time frame: up to 72 hours

07

Study locations

1 site
  • The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital)
    Shandong, Jinan 100021, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2026 to primary completion in Jul 2026, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2026
First posted
Apr 16, 2026
StartActual
May 20, 2026
Primary completionActual
Jul 2, 2026
CompletionActual
Jul 29, 2026
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07534176
Responsible party
Sponsor
First posted
Apr 16, 2026
Start date
May 20, 2026
Primary completion
Jul 2, 2026
Completion
Jul 29, 2026
Last update
Sep 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GS1-144

Start the discussion